Clinical Trial Update: Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

A randomized multicenter Phase II/III trial comparing adjuvant gemcitabine to neoadjuvant/adjuvant FOLFIRINOX for resectable pancreatic carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Resectable Pancreatic Carcinoma

Drugs mentioned

• FOLFIRINOX
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Krankenhaus Nordwest | Conditions: Resectable Prancreas Carcinoma | Phase 2, Phase 3 | Status: COMPLETED